Ratings Hualan Biological Vaccine Inc.

Equities

301207

CNE1000058J9

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 10/05/2024 am IST			5-day change	1st Jan Change
22.41 ^CNY	-3.20%		+1.96%	-19.39%

25/04	Hualan Biological Vaccine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
01/04	Hualan Biological Vaccine Inc. Proposes Final Cash Dividend for 2023	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
HUALAN BIOLOGICAL VACCINE INC.	-19.39%	1.86B	-
CSL LIMITED	-2.61%	89.08B	A-
SAMSUNG BIOLOGICS CO.,LTD.	+3.55%	40.9B	A-
BIOGEN INC.	-14.40%	32.25B	B-
UCB	+55.89%	25.14B	A
BIOMARIN PHARMACEUTICAL INC.	-15.96%	15.39B	C
INCYTE CORPORATION	-15.50%	11.91B	B-
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.29%	11.89B	B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.75%	11.64B	D+
SWEDISH ORPHAN BIOVITRUM AB	+7.87%	9.03B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes